Clinical decision making locoregional therapy in hcc

Clinical decision-making regarding locoregional therapy in patients with hepatocellular carcinoma (HCC) requires a comprehensive assessment of tumor burden, liver function, presence of microvascular invasion (MVI), patient performance status, and potential for downstaging or curative intent. Locoregional therapies, such as transarterial chemoembolisation (TACE), ablation techniques (radiofrequency, microwave, or cryoablation), hepatic arterial infusion chemotherapy (HAIC), and selective internal radiation therapy (SIRT or TARE), form cornerstone treatments particularly for patients with early and intermediate-stage HCC and preserved liver function Chen et al. 2026 Morishita et al. 2026.

Key considerations include the stage and extent of disease—patients with low tumor burden (for example, within up-to-seven criteria) should prioritize optimizing local therapies to improve complete response and long-term outcomes, whereas those with higher tumor burden or MVI positivity may benefit from combination strategies integrating locoregional and systemic therapies Chen et al. 2026 Chen et al. 2026 Yang et al. 2025. Preserved liver function, often Child-Pugh class A, and performance status (ECOG 0 or 1) are essential to safely deliver locoregional treatments and to avoid hepatic decompensation SmPC YERVOY,SmPC OPDIVO,Chen et al. 2026 Morishita et al. 2026.

TACE remains the standard first-line locoregional therapy for intermediate-stage HCC in suitable candidates, delivering chemotherapy via hepatic artery embolization, inducing ischemic necrosis of tumor tissue. However, due to heterogeneity in tumor burden and biology at this stage, uniform TACE is insufficient, prompting subclassification systems to better predict prognosis and treatment response Chen et al. 2026 Chen et al. 2026. Combining TACE with targeted therapies such as tyrosine kinase inhibitors (e.g., sorafenib or lenvatinib) and immune checkpoint inhibitors improves progression-free survival, particularly in patients with high tumor burden and/or MVI, highlighting the importance of multidimensional stratification Chen et al. 2026 Chen et al. 2026.

Ablative therapies such as radiofrequency ablation (RFA), microwave ablation, and cryoablation are effective for small tumors (<3 cm) or as adjuncts to resection or transplantation. Cryoablation offers immunomodulatory properties and visualization advantages, though tumor location (e.g., near large vessels or bile ducts) impacts eligibility due to heat sink effects or injury risk. Ablation is also used for downstaging or bridging to transplant Chen et al. 2026 Morishita et al. 2026.

Selective internal radiation therapy (TARE), using yttrium-90 microspheres, is increasingly employed for intermediate or high tumor burden HCC, showing superior time to progression and overall survival compared to drug-eluting bead TACE in some studies, and a favorable safety profile. Combining TARE with immunotherapy or targeted therapy is an emerging strategy with promising efficacy, especially in high tumor burden scenarios Chen et al. 2026 Chen et al. 2026 Morishita et al. 2026.

Locoregional therapy decisions must also integrate tumor biology markers such as alpha-fetoprotein (AFP), where elevated levels (e.g., ≥400 ng/mL) identify subgroups that may benefit from additional systemic agents like ramucirumab. Furthermore, liquid biopsies and inflammatory/immune status biomarkers (e.g., neutrophil-to-lymphocyte ratio) are gaining importance for patient stratification in locoregional treatment selection and outcome prediction Chen et al. 2026 Chen et al. 2026 Zerehpoosh et al. 2026.

Dynamic monitoring of liver function is critical throughout treatment as locoregional therapies may impair hepatic reserve, especially in patients with borderline Child-Pugh scores (7–9), necessitating treatment adjustments and multidisciplinary management to balance efficacy and safety Chen et al. 2026 Chen et al. 2026 Morishita et al. 2026. Multidisciplinary team evaluation is essential to individualize treatment plans, considering liver status, tumor characteristics, patient comorbidities, and potential for curative versus palliative intent Chen et al. 2026 Yang et al. 2025.

Patient eligibility for liver transplantation after locoregional control or downstaging remains a crucial consideration, guided by criteria such as the Milan or expanded UCSF criteria, with locoregional therapies serving as a bridge or conversion strategy Chen et al. 2026 Yang et al. 2025 Morishita et al. 2026. The risk of variceal bleeding with therapies involving antiangiogenic agents (e.g., bevacizumab with atezolizumab) requires prior evaluation for esophageal varices and appropriate management SmPC Tecentriq.

In summary, clinical decision-making for locoregional therapy in HCC hinges on precise patient selection using tumor burden, liver function, and biological markers, with preference for combining locoregional modalities with systemic targeted or immunotherapies in selected patients to improve outcomes while preserving hepatic function and quality of life SmPC YERVOY,SmPC OPDIVO,SmPC Tecentriq,Chen et al. 2026 Morishita et al. 2026 Chen et al. 2026.